Proactive Investors - Run By Investors For Investors

Horizon Discovery completes US$85mln Dharmacon acquisition

The US$85mln deal was announced in July and funded through cash and shares
picture of handshake
The US$85mln deal was announced in July

Horizon Discovery Group PLC (LON:HZD) has completed the acquisition of GE healthcare business Dharmacon.

The US$85mln deal was announced in July and funded through cash and shares and an accompanying £80mln placing.

WATCH: Acquisition gives Horizon Discovery a 'full and complete suite of tools' to power growth

Darrin Disley, Horizon Discovery’s chief executive, said in a statement: "We are delighted to have completed the transformational acquisition of Dharmacon and look forward to working closely with our new colleagues and providing an expanded array of research solutions to a cumulative customer base now exceeding 10,000 in number. 

“Dharmacon is a global leader in gene modulation products with a fast growing gene-editing product portfolio which are highly complementary to the gene editing, translational genomics, personalised medicine, cell and gene therapy products and services of Horizon."

READ: Horizon Discovery can be transformed by Dharmacon acquisition suggests RBC

He added: “The combined business creates a global leader in the application of gene modulation and gene editing technologies - two rapidly growing and important areas of life science research.

"We expect the strong commercial synergies in markets, sales channels, and brand strength to accelerate revenue growth and margin expansion.”

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use